NeuroTherapia Secures $12M in Series B Funding for Groundbreaking Neuroinflammation Therapies

In an exciting stride toward advancing neurotherapeutics, NeuroTherapia, Inc. has successfully secured $12 million in funding to support its mission of developing groundbreaking therapies for diseases driven by neuroinflammation. Founded in 2015 by visionary co-founders Drs. Mohamed Naguib and Joseph Foss, NeuroTherapia is at the forefront of research and innovation, with a particular focus on its lead compound, NTRX-07 (previously known as MDA7). NTRX-07 has demonstrated the potential to significantly reduce the activation of microglial cells in the brain, effectively decreasing inflammation that can contribute to nerve cell injury and neuropathic pain often experienced following nerve injuries or as a result of chemotherapy. Promisingly, early research suggests that inhibiting this neuroinflammation might also play a crucial role in reversing cognitive deterioration associated with Alzheimer's Disease (AD). The funding will facilitate the progression of NeuroTherapia's roadmap, enabling the anticipated Phase 2 clinical trial for NTRX-07 in AD patients, slated to begin in 2025, as well as further trials for other neuroinflammatory conditions. Spearheaded by industry leaders such as CEO Tony Giordano, Ph.D., alongside seasoned experts like Joseph Foss, M.D., and Marianna Kiraly, Ph.D., the team boasts a wealth of experience in clinical pharmacology and neuroscience research. This new infusion of capital reinforces NeuroTherapia’s commitment to pioneering effective treatments that could drastically alter the lives of those affected by debilitating neuropathic conditions and ultimately pave the way for a future free from the constraints of neuroinflammation-related diseases.